Durata Therapeutics, Inc. Reports Fourth Quarter And Full-Year 2013 Financial Results

Published: Mar 14, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHICAGO, March 14, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced its fourth quarter and full year 2013 financial results.

"2013 was a year of incredible achievement for Durata, including data presentations of our DISCOVER programs, accepted regulatory submissions of dalbavancin in the U.S. and E.U., and activities to prepare for commercialization. In addition, we strengthened our balance sheet with equity and debt financings that give us operational flexibility," said Paul R. Edick, Chief Executive Officer of Durata Therapeutics. "2014 looks to be an exciting year for Durata as we continue to build an organization focused on the goal of increasing patient well-being while simultaneously improving efficiency of health care delivery."

Help employers find you! Check out all the jobs and post your resume.

Back to news